CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer

被引：0

作者：

Lee, J. ^{[1
]}

Tsuboi, M. ^{[2
]}

Garrido, P. ^{[3
]}

Kim, E. S. ^{[4
]}

Dong, T. ^{[5
]}

Blin, C. ^{[6
]}

Rodrik-Outmezguine, V. ^{[5
]}

Mookerjee, B. ^{[5
]}

Passos, V. ^{[5
]}

Mok, T. ^{[7
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Natl Canc Ctr Hosp East, Thorac Surg, Kashiwa, Chiba, Japan

[3] Hosp Ramon Y Caja, Madrid, Spain

[4] Atrium Hlth, Levine Canc Inst, Dept Solid Tumor Oncol, Charlotte, NC USA

[5] Novartis Pharmaceut, E Hanover, NJ USA

[6] Novartis Pharma Ag, Basel, Switzerland

[7] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

关键词：

IL-1; beta; canakinumab; pembrolizumab; NSCLC; neoadjuvant; surgery; major pathological response;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P03.05

引用

页码：S260 / S260

页数：1